Saruparib

Biliary Tract Cancer

AstraZenecaSmall moleculePhase 1/2Active

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 95/ 100

Competitive context

82 Active assets in the Biliary Tract Cancer cohort.

Asset / Sponsor	Phase	Rating
Cis-Diamminedichloroplatinum Ii Merck Sharp & Dohme LLC	Phase 3	BB
Epirubicin Merck Sharp & Dohme LLC	Phase 3	BB
Pembrolizumab Merck Sharp & Dohme LLC	Phase 3	BB
Fluorouracilum Shenzhen Xinhe Biomedical	Phase 2	B
Capecitabine Zhejiang Cancer Hospital	Phase 2	B

View all 50 →

Same molecule, other indications

Saruparib is also rated in:

metastatic prostate carcinomaActive

BB

Indicative · Phase 3

66 / 100

small cell lung carcinomaActive

B

Indicative · Phase 2

60 / 100

prostate cancerActive

B

Indicative · Phase 3

58 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.